Bispecific and monospecific antibodies using novel anti-PD-1 sequences

1. A method for treating cancer comprising administering to a patient in need thereof:

a) a heterodimeric bispecific antibody that binds CTLA-4 and LAG-3; and

b) an anti-PD-1 antibody,

wherein said heterodimeric bispecific antibody comprises:

i) a first monomer comprising

A) a single chain Fv domain (scFv) that binds human CTLA-4, wherein said scFv domain comprises:

1) a first variable heavy domain (VH1);

2) a scFv linker; and

3) a first variable light domain (VL1); and

B) a first variant Fc domain;

ii) a second monomer comprising a VH2-CH1-hinge-CH2-CH3 heavy chain, wherein VH2 is a second variable heavy domain and CH2-CH3 is a second variant Fc domain; and

c) a light chain comprising a second variable light domain (VL2) and a constant light domain (CL);

wherein said VH2 and said VL2 bind LAG-3, wherein said VH1 comprises a vhCDR1 comprising the amino acid sequence of SEQ ID NO:35616, a vhCDR2 comprising the amino acid sequence SEQ ID NO:35617 and a vhCDR3 comprising the amino acid sequence of SEQ ID NO:35618, said VL1 comprises a vlCDR1 comprising the amino acid sequence of SEQ ID NO:35619, a vlCDR2 comprising the amino acid sequence SEQ ID NO:35620 and a v1CDR3 comprising the amino acid sequence of SEQ ID NO:35621, and wherein said VH2 comprises a vhCDR1 comprising the amino acid sequence of SEQ ID NO:35609, a vhCDR2 comprising the amino acid sequence SEQ ID NO:35610 and a vhCDR3 comprising the amino acid sequence of SEQ ID NO:35611, said VL2 comprises a vlCDR1 comprising the amino acid sequence of SEQ ID NO:35624, a vlCDR2 comprising the amino acid sequence SEQ ID NO:35625 and a vlCDR3 comprising the amino acid sequence of SEQ ID NO:35626.

2. A method according to claim 1 , wherein said VH1 comprises SEQ ID NO:35613, VL1 comprises SEQ ID NO:35614, VH2 comprises SEQ ID NO:35608 and VL2 has SEQ ID NO:35623.

3. A method for treating cancer comprising administering to a patient in need thereof:

a) a heterodimeric bispecific antibody that binds CTLA-4 and LAG-3; and

b) an anti-PD-1 antibody,

wherein said heterodimeric bispecific antibody comprises:

i) a first monomer comprising

A) a single chain Fv domain (scFv) that binds human CTLA-4, wherein said scFv domain comprises:

1) a first variable heavy domain (VH1);

2) a scFv linker; and

3) a first variable light domain (VL1); and

B) a first variant Fc domain;

ii) a second monomer comprising a VH2-CH1-hinge-CH2-CH3 heavy chain, wherein VH2 is a second variable heavy domain and CH2-CH3 is a second variant Fc domain; and

c) a light chain comprising a second variable light domain (VL2) and a constant light domain (CL);

wherein said VH2 and said VL2 bind LAG-3,

wherein said first monomer comprises SEQ ID NO:35612, said second monomer comprises SEQ ID NO:35607 and said light chain comprises SEQ ID NO:35622.

4. A method for treating cancer comprising administering to a patient in need thereof:

a) a heterodimeric bispecific antibody comprising:

i) a first monomer comprising SEQ ID NO:35612;

ii) a second monomer comprising SEQ ID NO:35607; and

iii) a light chain comprising SEQ ID NO:35622; and

b) an anti-PD-1 antibody.